DailyIQ
|
Sector:HealthcareAll sectors
Last updated5 minutes ago

RVMD·Revolution Medicines, Inc.

$210.16
-0.71 (-0.34%)
Market Closed (Overnight)$210.50+0.34 (+0.16%)
High
$211.60
Open
$209.15
Market Cap
45.15B
52W High
$225.01
Low
$207.48
P. Close
$210.16
P/E
-
52W Low
$39.17
Fwd P/E
-35.86
DailyIQ Est.
$265.62
Inst. Ownership
69.9%
Short Interest
4.53%
Days to Cover
6.4
Technical Score (1D)
73
BUY
News Sentiment
50
MIXED
Revolution Medicines’ FDA approval of Rasonque for metastatic pancreatic cancer is the most immediate catalyst, as the Phase 3 data showed a 60 % reduction in death risk and a median overall survival of 13.2 months versus 6.7 months with chemotherapy. The company has set a wholesale acquisition cost of $39,800 for a 30‑day supply, implying a large revenue potential once reimbursement is secured, but payer coverage remains uncertain. This approval could shift the company’s valuation toward a revenue‑generating model, yet the lack of any current sales means the impact on cash flow will be delayed until reimbursement and market uptake materialize. In the same week, the company reported a Q2 2026 adjusted loss of $2.34 per share, wider than consensus, with no revenue and R&D expenses up 76 % to $395 million, underscoring its continued cash burn and the absence of near‑term income streams. The juxtaposition of a promising product launch with a weak earnings report highlights the risk that the approval may not translate into immediate financial performance. Over the past five years, Revolution has outperformed the market with a 46.85 % annualized return, but that growth has been driven by historical momentum rather than new catalysts, suggesting that recent developments are the primary drivers of future performance. For the next 1–10 trading days, watch for any early reimbursement decisions or payer negotiations that could validate the high price point and begin to generate revenue. Also monitor any updates on the commercial launch timeline, as delays could further strain the company’s cash position. Finally, keep an eye on broader oncology pricing trends, as changes in reimbursement policy for high‑cost therapies could affect Rasonque’s market penetration and overall profitability.
Earnings Summary
Revolution Medicines is a clinical‑stage oncology biotech focused on RAS‑targeted therapies, positioning itself within the precision oncology sector. The company’s pipeline includes Phase 1 RAS(ON) inhibitors daraxonrasib and elironrasib, and Phase 2 RMC‑4630 companion inhibitors, all aimed at cancers driven by RAS mutations. Recent quarterly results show continued losses, with Q4 2024 EPS of –$1.12 versus an estimate of –$0.96 and zero revenue reported, and Q2 2026 EPS of –$2.34 against an estimate of –$2.02, again with no revenue. The company’s earnings trend reflects ongoing clinical development costs and the absence of commercial sales, with EPS deteriorating from –$1.12 to –$2.34 over the two quarters. Historically, the firm has posted negative earnings each quarter, with no revenue streams to offset R&D spend, and has consistently missed analyst EPS estimates. The pattern of losses is consistent with a clinical‑stage biotech awaiting product launch. Recent news highlights a pivotal FDA approval of Rasonque for metastatic pancreatic cancer, a first‑in‑class oral RAS inhibitor, and an upgrade to Outperform with a $320 price target by Evercore ISI. This regulatory milestone shifts the company from a purely clinical stage to a commercial stage, potentially generating revenue in the near term. Investors should watch the timing of the commercial launch, the transition of patients from the expanded access program to commercial supply, and early sales data that will indicate market uptake. The first quarterly earnings release post‑launch will be critical to assess whether the approval translates into revenue and whether the company can begin to offset its R&D costs with commercial cash flow.

EPS

EstBeatMiss
$-2.66$-2.18$-1.70$-1.22$-0.74Q4'24Q2'26Q3'26
QtrEstActual+/−
Q3'26$-2.44 - -
Q2'26$-2.02$-2.34-16.0%
Q4'24$-0.96$-1.12-16.1%

Revenue

EstBeatMiss
$-3M$3M$8M$14M$19MQ4'24Q2'26Q3'26
QtrEstActual+/−
Q3'26$12M - -
Q2'26$17M$0-100.0%
Q4'24 - $0 -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

RVMD Stock Snapshot

BUY73/100
$210.50+$0.34 (0.2%)
Market cap
45.15B
Day range
$207.48 – $211.60
News sentiment
50/100 · Neutral
Analyst target
$248.77 (+18.2%)
Consensus
Buy · 30 analysts
52-week range+437.4% off low · -6.4% from high
$39.17$225.01
Price $210.50 DailyIQ Est. $265.62

The signal on RVMD is bullish: price action is confirming the underlying trend, not fighting it. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Behaviour On Record

What RVMD's own history says about today's numbers

Realized volatility (21d)
34.9% 10th pct
Below its peak
-4.9%
vs 200-day average
+58.7%
Up days (1y)
57%

Revolution Medicines, Inc. is currently running 34.9% annualised volatility over the last 21 sessions. Measured against RVMD's own 6 years of daily returns rather than a market-wide average, that is the 10th percentile — unusually subdued by its own history, against a typical reading of 55.7%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

RVMD is trading -4.9% below its running peak. Across 6 full years on file, its median worst-drawdown-in-a-year was -44.2%, and the deepest was -55.9% in 2021. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +58.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 88th percentile — a wider gap than this stock usually carries. Over the past year RVMD closed higher on 57% of sessions, and it is currently 1 session into a rising streak.

On September specifically: over 6 years of records, RVMD finished the month higher 3 of 6 times, with a median return of +1.2% and an average of +3.1%. Its strongest month historically has been November at +16.1% on average, its weakest May at -2.2%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: RVMD has opened more than 2% away from the prior close in 268 of 1,647 sessions (16.3% of the time), with the largest gaps running +24.8% and -20.5%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 1,648 daily closes between 2020-02-13 and 2026-09-03, split-adjusted, recomputed daily. Percentiles are against RVMD's own 7-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of RVMD's sector?

Revolution Medicines, Inc. sits in the Health Care sector, currently ranked 2nd of 11 GICS sectors by relative-strength rotation score (weakening).

Sector rank
#2 of 11
Sector state
Weakening
Sector rotation score
90

Options Market

What is the options market pricing for RVMD?

CallsPuts

For Revolution Medicines, Inc.'s nearest expiry (2026-09-18, 13 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.30), with at-the-money implied volatility around 54.3%. The options market is pricing roughly a ±9.6% move by that expiry — a range of about $184.18–$223.24.

Put/call ratio (2026-09-18)
0.30
ATM implied volatility
54.3%
Total open interest
20,202
Expected move by 2026-09-18
±9.6% ($184.18–$223.24)

RVMD Competitive Positioning

Revolution Medicines, Inc. (RVMD) is tracked alongside these names in Biotechnology on DailyIQ — ranked by market cap, with today's move alongside.

Held by These ETFs

RVMD is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.